CordenPharma, Evotec, Sartorius Expand; Adare Biome Names President

By Miranda Greenberg -

April 22, 2021

The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, Evotec, Adare Pharma Solutions, Sartorius, Nanoform, and Aprecia.

Biologics manufacturing

Evotec Initiates Construction of New Biologics Mfg Facility
Evotec, a Hamburg, Germany-based drug-discovery and development company, has initiated construction of a new biologics manufacturing facility at its campus in Toulouse, France.

The facility will be Evotec’s second biomanufacturing facility and its first commercial biomanufacturing facility in Europe. Construction of the new European facility is expected to begin in the first half of 2021 and is expected to be fully operational in 2023. The construction of Evotec’s first facility in Redmond, Washington is proceeding on schedule and will be fully operational in the second half of 2021.

The build-up of the biomanufacturing facility in Europe will be supported with up to EUR 50 million ($60 million) from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne Prefecture as well as Toulouse Métropole. The total investment that Evotec plans to undertake is currently estimated at approximately EUR 150 million ($180 million).

Source: Evotec


Sartorius Opens New Downstream Processing Equipment Facility
Sartorius, a provider of products and services for the life sciences, has opened a new manufacturing facility for downstream equipment in Havant, UK.

The opening marks the official relocation of more than 90 employees to the new 58,000-square-foot site, located near its former site in Portsmouth, UK. In April 2020, Sartorius acquired select life-science businesses from Danaher Corporation, including a production facility for downstream processing equipment in Portsmouth, UK. The new facility in Havant will manufacture a range of systems for the biopharmaceutical market, including chromatography columns and filtration systems.

In addition to a 28,000-square-foot production area, the center accommodates a 4,000-square-foot test lab to demonstrate the functionality of Sartorius equipment.

In 2021, Sartorius says it will invest more than EUR 400 million ($481 million) in the expansion of manufacturing capacities globally. In line with these investments, Sartorius aims to expand its Havant site, With its new facility in Havant, Sartorius now has five locations in the UK, employing over 900 staff members.

Source: Sartorius


Formulation Development/Drug-Product Manufacturing

CordenPharma To Expand Lipid Excipients Purification Capacity
CordenPharma has announce a capital expenditure initiative to further enhances its lipid purification capacity at its facility in Boulder, Colorado.

The expansion includes additional production lines to be incorporated into the lipid manufacturing process as early as April 2021. By the end of July 2021, the company says this investment will decrease its lipid shipment delivery time.

Due to the increasing demand for mRNA COVID-19 vaccines formulated with lipid nanoparticle (LNP) delivery systems, CordenPharma has been investing in expanded lipid supply chains at its facilities in Switzerland, France, and Colorado.

CordenPharma manufactures four lipids that are typically used to formulate LNPs for various synthetic mRNA-based vaccines: (1) cationic lipids that encapsulate the negatively charged mRNA; (2) PEGylated lipids that help to form a protective hydrophilic layer which sterically stabilizes the LNP; (3) DiStearoylphosPhatidylCholine (DSPC), a phospholipid that provides a stable bilayer-forming structure; and (4) plant-based cholesterol (CP BotaniChol), which stabilizes the LNP structures and facilitates endosome escape.

Source: CordenPharma


Nanoform, Aprecia To Advance 3D-Printed Drug Dosage Forms
Nanoform, a Helsinki, Finland-based drug-enabling nanotechnology company, and Aprecia Pharmaceuticals, a Langhorne, Pennsylvania-based specialty pharmaceutical company with a three-dimensional printing (3DP) platform, are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms.

The immediate product innovation target for the collaboration is to combine Nanoform’s fast- dissolution nanoformed particles with Aprecia’s ZipDose technology platform for rapid disintegration to enable buccal and oral delivery of medicines. The companies say additional benefits may include lower dosage products, less excipient content, and reduced pill burden.

Source: Nanoform and Aprecia


General

Adare Pharma Solutions Appoints New President of Adare Biome
Adare Pharma Solutions, a CDMO and provider of pharmaceutical technologies, has appointed Ludger Roedder as President of Adare Biome, a division of Adare Pharma Solutions that focuses on microbiomes.

In the newly created role of President of Adare Biome, Mr. Roedder will assume responsibility for the entire microbiome business, including postbiotics, and serve as a member of Adare’s Executive Leadership Team.

Mr. Roedder has more than 30 years of global business and marketing leadership to Adare and expertise in animal and human nutrition, including probiotics and enzymes. He has successfully led business growth through commercial development and successful M&A in Europe, Asia, South America, and the US in the animal and human nutrition sectors. Prior to joining Adare Biome, Mr. Roedder was Chief Business Officer at BRAIN AG, where he held responsibility to commercialize the business on a global scale and served as a member of the Management Board. Previously, Mr. Roedder held positions of increasing responsibility at BASF Corporation from 2005-2018.

Source: Adare Pharma Solutions